Heart Failure, Congestive
Conditions
Keywords
guideline adherence, systolic heart failure
Brief summary
The purpose of this study is to survey the guideline compliance of the cardiologists in the treatment of systolic heart failure in Korea
Detailed description
Major improvement in the medical management of CHF has been achieved in the past decades. But there is no doubt that prognosis of heart failure patients remains poor. The compliance to the standard treatment can be one of reasons. But very little data concerning this in Korea is available.
Interventions
OTHERguideline adherence
guideline adherence of physician
Sponsors
GlaxoSmithKline
Study design
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects admitted to hospital with systolic heart failure(LVEF under 45%) in 2009 * Subjects, age 20 or/and above * Subjects admitted to hospital (emergency area, to internal medicine or to cardiology wards, CCU or intensive care) with dyspnea and verification of heart failure based on following criteria; * Symptoms typical of heart failure : breathlessness at rest or on exercise, fatigue, tiredness, ankle swelling and Signs typical of heart failure : tachycardia, tachypnoea, pulmonary rales, pleural effusion, raised jugular venous pressure, peripheral oedema, hepatomegaly * Objective evidence of a structural or functional abnormality of the heart at rest : cardiomegaly, third heard sound, cardiac murmurs, abnormality on the echocardiogram, raised natriuretic peptide concentration
Exclusion criteria
* Subject who expired during hospitalization
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean of modified Guideline Adherence Indicator(mGAI-3) | 1year | Modified percentage based on each participant's condition |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of participants with each class drug prescribed | 1year | ARB, BB, ACE-I, aldosterone antagonist |
| Percentage of participants with daily target dose reached | 1year | ARB, BB, ACE-I, aldosterone antagonist |
| Percentage of all cause mortality | 1year | All cause mortality in 1-year after treatment of systolic heart failure |
| Percentage of All cause hospitalization | 1year | All cause hospitalization in 1-year after treatment of systolic heart failure |
| Mean of mortality or rehospitalization rate according to mGAI-3 | 1year | — |
Countries
South Korea
Outcome results
None listed